Zadno Reza

CEO Zadno Reza sold 15,916 shares at $61.31 on 2025-03-06; stock -42.1% from 52-week high, 5 of 5 prior PRCT sales well-timed.

Zadno Reza (President, CEO) sold 15,916 shares of PRCT at $61.31 on 2025-03-06, reducing holdings by 8.2% to 178,545 shares post-transaction. The stock has declined substantially since the sale: -17.2% over 30 days and -36.8% over 90 days, placing it -42.1% from its 52-week high of $99.45. Notably, his cross-ticker track record shows a 100.00% well-timed rate on 16 prior sales with an average 90-day return of -31.4%, and at this specific ticker (PRCT), all 5 of his prior sales were well-timed, with 90-day post-sale declines ranging from -32.4% to -35.5%. While PRCT reported strong revenue growth of +64.8% annually and generated $58.4M in latest quarterly revenue, the company remains unprofitable with a net loss of $-21.0M over its most recent full fiscal year. The consistent pattern of well-timed sales coupled with deteriorating stock price and company-wide unprofitability warrants close investor attention to fundamentals and forward guidance.

CEO Zadno Reza sells 26,423 shares of PRCT for $2,568,844.46 in four transactions on 2024-12-04

Zadno Reza, President and CEO of PROCEPT BioRobotics, executed four separate sales totaling 26,423 shares for $2,568,844.46 (blended average $97.22) on 2024-12-04, reducing his holdings by 14.7% to 152,762 shares. The sales occurred near the stock's 52-week high of $99.45, with the current price at $94.84 now 4.6% below the high. This comes after Reza's prior sales on 2024-11-27 and 2024-11-20 at the same ticker—five recent transactions within two weeks. The company's fundamentals show revenue of $58,370,000.00 for the latest quarter with significant annual growth of +81.6%, but the company remains unprofitable with net income of -$20,974,000.00 over its most recent full fiscal year. Investors should note the cumulative reduction in CEO holdings in a short window and monitor the company's path to profitability given its current operating losses.

PRCT CEO Reza sold 26,420 shares for $2.6M at $97.83 avg; 5th sell in 8 days, stock near 52-week high

Zadno Reza, President and CEO of PROCEPT BioRobotics, executed 4 separate sales on November 27, 2024, totaling 26,420 shares (26.4K shares) for $2,584,637.90 ($2.6M) at a blended average price of $97.83. This sale reduced his holdings by 12.8% and marks the fifth insider sell at PRCT in eight days (three sales on November 20, two on November 13). The sales occurred near the stock's 52-week high of $99.27, with the current price at $96.11 now -3.2% from peak. While the company reported strong revenue growth of 81.6% year-over-year, it remains unprofitable with a net income loss of $-20,974,000.00 ($-21.0M) over the latest full fiscal year. The rapid cadence of CEO selling at elevated valuations against the backdrop of continued losses warrants observation of whether this signals portfolio management or changing conviction at a high-valuation, unprofitable growth-stage company.

PRCT CEO Zadno Reza sells 26,420 shares (11.4% of holdings) for $2,445,723.67; stock up 39% in 30 days despite unprofitable fundamentals

Zadno Reza, CEO, executed 3 separate sales totaling 26,420 shares for $2,445,723.67 on 2024-11-20, reducing holdings from 232,025 to 205,605 shares. This follows a pattern of multiple sales at the same ticker over the prior week (5 prior trades at PRCT, with 4 on 2024-11-13 and 1 on 2024-10-30). The timing of these dispositions is notable: the stock has risen 39.0% over the past 30 days and is currently at $93.60, near its 52-week high of $99.07, despite the company reporting a net loss of $20,974,000 on revenue of $58,370,000 in the latest quarter. The concentration of insider selling during a steep price appreciation run, coupled with persistent unprofitability despite 81.6% annual revenue growth, suggests the CEO may be capitalizing on elevated valuations rather than signaling renewed confidence in the business fundamentals.

PRCT CEO Zadno Reza sold 26,420 shares in 4 transactions for $2,485,572.71 on 2024-11-13

Zadno Reza, President and CEO of PROCEPT BioRobotics, executed 4 separate sales totaling 26,420 shares for $2,485,572.71 at prices ranging from $92.74 to $95.58, representing a -10.2% reduction in his 258,445 pre-transaction holdings. The company is unprofitable (net income $-20,974,000.00) despite strong revenue growth of +81.6% year-over-year, with a market cap of $4,641,172,384.96. Reza's cross-ticker track record shows only 1 prior sale, so there is minimal historical baseline for evaluating sale patterns. The current stock price of $88.94 trades 10.2% below the 52-week high of $99.07, having declined from the transaction prices achieved 5 weeks ago.

CEO Zadno Reza sold 288,461 shares of PRCT at $91.00 (−52.7% of holdings) for $26,249,951.00

Zadno Reza, President and CEO of PROCEPT BioRobotics, executed a substantial sell of 288,461 shares at $91.00 on 2024-10-30, reducing his holdings by 52.7% from 546,906 shares to 258,445 shares and generating $26,249,951.00 in proceeds. The transaction occurred near the stock's 52-week high (current $90.00 vs. 52-week high $96.69, −6.9%), following a strong 90-day run of +56.8% and 30-day performance of +18.1%. PROCEPT is unprofitable (net income −$20,974,000.00 in the latest period) despite robust 81.6% annual revenue growth, operating in a pre-profitability growth mode. The magnitude and timing—a near-complete halving of the CEO's direct equity stake at an elevated price point after sustained momentum—warrant investor scrutiny of strategic intent and forward guidance.